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Abstract
Peripheral neuroblastic tumors (PNTs) share a common origin in the sympathetic nervous system, but manifest variable
differentiation and growth potential. Malignant neuroblastoma (NB) and benign ganglioneuroma (GN) stand at opposite
ends of the clinical spectrum. We hypothesize that a common PNT progenitor is driven to variable differentiation by specific
developmental signaling pathways. To elucidate developmental pathways that direct PNTs along the differentiation
spectrum, we compared the expression of genes related to neural crest development in GN and NB. In GNs, we found
relatively low expression of sympathetic markers including adrenergic biosynthesis enzymes, indicating divergence from
sympathetic fate. In contrast, GNs expressed relatively high levels of enteric neuropeptides and key constituents of the
Hedgehog (HH) signaling pathway, including Dhh, Gli1 and Gli3. Predicted HH targets were also differentially expressed in
GN, consistent with transcriptional response to HH signaling. These findings indicate that HH signaling is specifically active
in GN. Together with the known role of HH activity in enteric neural development, these findings further suggested a role
for HH activity in directing PNTs away from the sympathetic lineage toward a benign GN phenotype resembling enteric
ganglia. We tested the potential for HH signaling to advance differentiation in PNTs by transducing NB cell lines with Gli1
and determining phenotypic and transcriptional response. Gli1 inhibited proliferation of NB cells, and induced a pattern of
gene expression that resembled the differential pattern of gene expression of GN, compared to NB (p,0.00001). Moreover,
the transcriptional response of SY5Y cells to Gli1 transduction closely resembled the transcriptional response to the
differentiation agent retinoic acid (p,0.00001). Notably, Gli1 did not induce N-MYC expression in neuroblastoma cells, but
strongly induced RET, a known mediator of RA effect. The decrease in NB cell proliferation induced by Gli1, and the similarity
in the patterns of gene expression induced by Gli1 and by RA, corroborated by closely matched gene sets in GN tumors, all
support a model in which HH signaling suppresses PNT growth by promoting differentiation along alternative neural crest
pathways.
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Introduction
Peripheral neuroblastic tumors (PNTs) comprise a spectrum of
neural crest (NC) derived neoplasms that occur along the
sympathetic chain, ranging in state of differentiation and
malignancy. Ganglioneuromas (GNs) are benign tumors at the
most differentiated end of the spectrum, composed of large
neuronal cells, surrounded by satellite cells resembling glia.
Neuroblastomas (NBs) span the rest of the spectrum, varying in
malignancy and displaying variable degrees of neural and glial
differentiation [1]. Clinically, the position of a PNT along the
spectrum is not invariably fixed, as metastatic, poorly differenti-
ated tumors can undergo spontaneous regression. When these
tumors regress, they may necrose or transform into GNs [2]. PNTs
thus demonstrate a dynamic inverse correlation between differen-
tiation and malignancy, suggesting that inducing differentiation
may be a potent therapeutic strategy [3].
Developmental signaling pathways may regulate differentiation
in PNTs. To identify candidate developmental signals, we
analyzed differential expression of markers and determinants of
neural crest differentiation in GN and NB. We have previously
demonstrated that transcription factors advancing NC develop-
ment are expressed at higher levels in GN than NB [4]. Using
transcriptome-wide microarray analysis of GN and NB, we have
found that GNs, characterized by their advanced glial and
neuronal differentiation, diverge from the sympathetic phenotype
of their sites of origin. These highly differentiated, stroma-rich
tumors express genes typical of enteric neural and glial fate and
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pathway. We propose that Hedgehog pathway activity re-directs
PNTs from a sympathetic nervous system (SNS) differentiation
trajectory to an alternative neural crest trajectory, that of the
enteric nervous system (ENS).
SHH is a potent regulator of development throughout the
nervous system, and a potential oncogene. SHH is a mitogen for
diverse CNS progenitors, including cerebellar granule cell
precursors [5], and cells of the subventricular zone of the
cerebrum [6]. In the cerebellum, mutations that enhance HH
signaling are oncogenic, driving the formation of human
medulloblastomas, both sporadic and syndromic [7], and murine
medulloblastomas in transgenic Ptc+/2 and SmoA1 mice [8,9].
During peripheral neuro-ectodermal development, SHH is critical
for specific differentiation of NC cells of the cranium and the gut
[10,11].
As NC cells emerge from the dorsal neural tube, they are
outside the domain of SHH emanating from the ventral floor plate
[12]. Cranial NC cells, however, encounter SHH as they migrate.
HH signaling induces cranial NC cells to diverge from typical
neuroectodermal fate, giving rise to tissues characteristically of
mesodermal origin, including cranio-facial cartilage and bone, and
the cardiac outflow tracts [10]. NC cells from the vagal region
migrate into the embryonic gut and encounter SHH produced by
endodermal cells. For cranial and enteric NC cells, SHH acts as
mitogen and morphogen, regulating both proliferation and
differentiation [11,13].
While HH signaling is essential for NC development, and is
oncogenic in CNS progenitors, a role for HH signaling in PNTs
has not previously been defined. Our finding of increased HH
activity in GN suggested that the HH pathway might promote
PNT differentiation. To test the potential of HH signaling to effect
PNT behavior, we transduced NB cells with Gli1, a central effector
of the transcriptional response to HH signaling. We then analyzed
Gli1-transduced cells for effects on cell growth and gene expression
and compared the set of genes induced in NB cells by Gli1 to the
sets of genes induced by retinoic acid (RA) or differentially
expressed in GN compared to NB. Our findings demonstrate HH
signaling can re-direct developmental potential in PNTs, away
from typical SNS phenotype, promoting alternative differentia-
tion.
Results
Differential gene expression
Analysis of gene expression by microarray of 79 PNTs,
including 11 GNs and 68 NBs, strongly differentiated the two
sets of tumors. For each gene in the array, we compared
expression values for GNs and NBs by modified t-test [14]; 2500
probe sets representing 2107 genes were differentially expressed in
GN and NB with a p-value of ,0.0001 (Table S1). Among these
differentially expressed genes, several patterns emerged, demon-
strating that GNs differ from NBs not only in extent of
differentiation but also in specification within the range of
potential NC fates.
Catecholamine biosynthesis enzymes and sympathetic
neuropeptides are expressed more strongly by NB than
GN
Consistent with SNS phenotype, NBs expressed comparatively
high levels of catecholamine biosynthesis enzymes tyrosine
hydroxylase (TH), dopa-decarboxylase (DDC) and dopamine
beta-hydroxylase (DBH; Table 1). These proteins are strongly
expressed by sympathetic neurons. Chromogranin A and B
(CHGA, CHGB) and neuropeptide Y (NP-Y) are similarly
expressed throughout the sympathetic chain [15] and, in our
analysis, were specifically expressed in NBs (Table 1). The
relatively high expression of sympathetic markers in NB was
confirmed by qRT-PCR. GNs, in contrast, expressed these
sympathetic markers poorly (Table 1).
We confirmed the differential expression of sympathetic
markers in NB by immunocytochemistry for TH, DBH, CHGA
and CHGB. All of these markers demonstrated similar expression
patterns. Typical images of CHGA and DBH staining are shown
in Figure 1. In NB and adrenal medulla, large clusters of cells
strongly express TH and CHGA proteins in a cytoplasmic
distribution. In both GN and enteric ganglia, expression was
weaker and was limited to a subset of neurons, with many neurons
demonstrating no expression. Immunostaining for CHGB ap-
peared almost identical to CHGA, while TH strongly resembled
DBH (data not shown).
Differential expression of AP-2 transcription factors
distinguish GN from the sympathetic lineage
Transcription factors AP2-alpha and AP2-beta are homologous
genes expressed in succession during SNS development and
differentially expressed in GN and NB. Pre-migratory NC cells
express AP2-alpha and this protein is essential for all NC
development to proceed [16]. In contrast, post-migratory
sympathoblasts express AP2-beta, which is required for adrenergic
differentiation [17]. Microarray analysis confirmed, as we have
previously demonstrated, AP2-alpha is expressed at higher levels in
GN compared to NB [4]. In contrast, NBs expressed markedly
higher levels of AP2-beta (Table 2). The down-regulation of AP2-
alpha and complementary up-regulation of AP2-beta demonstrates
SNS commitment specific to NB and not found in GN.
Table 1. Measured abundance of mRNA for select genes
identified by microarray analysis as differentially expressed in
GN (italics) or NB (bold).
t-Test Fold change Fold change
microarray qRT-PCR qRT-PCR
Probe set Gene p-value NB/GN GN/NB
40808_s_at CHGA 4.4E-11
33426_at CHGB 6.3E-11 7.4
32943_at DBH 6.6E-10 3.2
32300_s_at TH 2.3E-05 38.2
38604_at NP-Y 0.0009 10.6
39668_at TFAP2B 2.5E-08 198.1
36299_at CGRP 0.02 7.1
33567_at VIP 0.04 12.5
40185_at GFAP 0.01 7.5
1198_at EDNRB 2.0E-24 9.2
33474_at GLI1 0.004 28.7
40358_at GLI3 3.0E-07 3.0
485_at DHH 5.1E-10 10.8
1736_at IGFBP6 2.1E-24 9.2
32154_at TFAP2A 3.4E-13
doi:10.1371/journal.pone.0007491.t001
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enriched in GN
While GNs expressed low levels of sympathetic markers, genes
abundant in the ENS were strongly expressed in GNs. To discern
ENS from SNS phenotype we analyzed expression of calcitonin
gene related peptide (CGRP), vasoactive intestinal peptide (VIP),
glial acidic fibrillary protein (GFAP), and endothelin B receptor
(EDNRB). CGRP and VIP are highly expressed in both enteric
neurons and dorsal root ganglion cells [18], but only sporadically
detectable in sympathetic neurons [19,20] GFAP is widely expressed
by enteric glia but uncommon in Schwann cells and limited to the
non-myelinating subset [21,22]. EDNRB is expressed during
development in both sympathetic and enteric progenitors as well
as melanoblasts but functionally required only for enteric and
melanocytic differentiation [23,24]. Microarray analysis and qRT-
PCR demonstrated that CGRP, VIP, GFAP and EDNRB were all
expressed at markedly higher levels in GN relative to NB (Table 1).
To demonstrate differential expression of ENS markers at the
cellular level, we used immunocytochemistry to detect GFAP and
CGRP in tumors and control tissues (Fig. 2). In NB, as in adrenal
medulla, rare scattered cells expressed CGRP. In contrast, in GN,
strong CGRP expression was detected in cell bodies of almost all
ganglion cellsand in neuritic processes. A similar pattern appeared in
the ENS, with frequent cytoplasmic labeling of neurons, and intense
labeling of axons (Fig. 2A). GFAP immunostaining in NB was
restricted to narrow chords ofstroma.GFAP labeling was alsoseen in
rare cells of the adrenal medulla. GN and ENS, however,
demonstrated extensive GFAP labeling with a similar fibrillary
appearance (Fig. 2B). We have previously demonstrated robust
expression of myelinproteins by glialcellsinGN[4];thecombination
of myelin proteins and GFAP distinguishes the glia of GN from non-
myelinating Schwann cells, suggesting instead an enteric glial
phenotype. Taken together, the differential expression of multiple
markers in GN confirms divergence from the sympathetic differen-
tiation trajectory, toward an ENS phenotype, an alternative NC fate.
Hedgehog pathway ligand and transcription factors are
expressed at high levels in GNs, with predicted effects on
known hedgehog target genes
Three homologous transcription factors are activated by the HH
pathway: GLI1, GLI2 and GLI3. Transcriptional activation of GLI1 is
a sensitive reporter of HH pathway activity[25]. Microarray and
qRT-PCR demonstrated differential expression of GLI1 and GLI3
in GN (Table 1). Of the 3 HH ligands, SHH and IHH were not
expressed at significantly different levels in GN or NB (data not
shown). DHH, however, was specifically expressed in GN (Table 1).
To determine the impact of differential expression of HH pathway
genes in GN we examined the expression of genes known to be
regulated by HH signaling. Microarray analysis demonstrated up-
regulation of established HHtargets, including IGFBP6 [26], cyclin D2
[27] and NR4a1 [28] (Table 2). To validate these observations, we
used qRT-PCR to confirm up-regulation of IGFBP6 in a second
independent set of GN (Table 1). Genes known to be down-regulated
Figure 1. Adrenergic markers CHGA (A) and DBH (B) were
expressed strongly in NB and weakly in GN. For each of these
genes, immunocytochemistry produced intense labeling of NB,
resembling the staining pattern of adrenal medulla (Ad). In contrast,
in both GN and enteric ganglia, labeling was less intense, and was
limited to a subset of neurons (red arrowheads), leaving other neurons
unlabelled (blue arrowheads). Dotted white lines highlight the margins
of the enteric ganglia.
doi:10.1371/journal.pone.0007491.g001
Table 2. Genes regulated by the HH pathway in other
systems were differentially expressed in GN relative to NB,
consistent with observed HH activity in GN.
t-Test
microarray
Probe set Gene p-value
1736_at IGFBP6 2.1E-24
36650_at cyclin D2 9.6E-29
37623_at NR4A2 8.3E-23
2047_s_at plakoglobin 4.4E-06
35084_at AMH 3.0E-05
Messages listed in italics were predicted to be up-regulated by HH activity and
were more abundant in GN. Messages listed in bold were predicted to be
down-regulated by HH activity and were less abundant in GN.
doi:10.1371/journal.pone.0007491.t002
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and plakoglobin [29] were specifically down-regulated in the GNs
(Table 2). The differential expression of HH targets in GN
demonstrates the active influence of the HH pathway.
Gli1 alters the proliferation rate of NB cells
To test whether HH pathway activity might direct PNT
behavior, we transduced NB cell lines with Gli1 together with GFP
or with GFP alone, and then sorted transduced cells to .95%
purity by FACS and analyzed proliferation rate and gene
expression. We verified Gli1 activity by transducing a GLI-
activated luciferase reporter plasmid (data not shown). Transduc-
tion of Gli1 profoundly affected the proliferation of NB cells
growing in culture (Fig. 3a,b).
We studied effects of Gli1 over-expression on five NB cell lines
with different characteristic patterns of growth: the rapidly
proliferating lines SH-SY5Y, BE2(S), BE2(N), BE2(C), and slow-
growing cell line SH-EP1. Gli1 reduced the proliferation rate of
each of the rapidly growing lines, while minimally affecting the
proliferation rate of SH-EP1 (Fig. 3a). In contrast, in explanted
murine cerebellar granule cell progenitors (CGCPs) transduction
with Gli1 increased proliferation rate 19-fold (Fig. 3a). To confirm
that Gli1 reduced in proliferation of NB cells, we prepared and
sorted to purity an independent set of SH-SY5Y cells transduced
with Gli1 and GFP (SY-Gli) or with GFP only (SY-GFP) and
quantified mitoses by PH3 immunostaining. SY-Gli1 cells
demonstrated 50% decreased mitotic rate, compared to SY-GFP
(Fig. 3b). Immunostaining for cleaved caspase-3, in contrast,
demonstrated no increase in apoptosis in the two populations (data
not shown).
Gli1 induces NB cells to express genes directing NC
development
We determined the transcriptional response of NB cells to Gli1
by comparing gene expression of SY-Gli1 and SY-GFP by
microarray hybridization. Diverse genes involved in NC develop-
ment were differentially expressed. We found Gli1 induced
differential expression of 193 out of 13,089 genes (228 out of
22,215 probe sets) on the U133 2.0 with a p-value of ,0.0001
(Table S2). Of these 193 genes, we selected 12 developmentally
relevant genes for confirmatory study by qRT-PCR, using
independently prepared sets of transduced SY5Y cells raised in
triplicate. qRT-PCR confirmed differential expression of 11 of 12
genes with a fold change of 2 or greater (Table 3). Up-regulation of
only one of these 12 genes, SOX2, could not be confirmed. We
also measured the expression of these 12 genes by qRT-PCR in
SH-EP1 cells transduced with Gli1 or GFP. 6 of the 12 genes tested
were up-regulated by Gli1 in SH-EP1 cells with a fold change of 2
or greater (Table 3), demonstrating both common elements in the
transcriptional response to Gli1, and as well as elements that vary
with the cellular context.
Among the 193 genes regulated by Gli1 in SY5Y cells were
crucial determinants of cranial and enteric NC development
(Table 4). Cranial NC genes up-regulated by Gli1 included KAL1
[30,31], MSX2 [32] and EDNRA [33,34]. Genes critical to ENS
development that were induced by Gli1 included RET [35] and
GFRA2 [36]. Gli1-regulated genes could also grouped by the
different cell types they specified (Table 4): KAL1, RET and GFRA2
regulate neural fates, while MSX2 and EDNRA direct the
development of bony NC derivatives. Gli1 induced glial
differentiation marker PMP22 and neuronal marker VMAT2,
demonstrating the potential of Gli1 to advance both neural and
glial differentiation (Table 4). The observed changes in prolifer-
ation and gene expression induced by Gli1 demonstrate the
potential for HH signaling to alter the behavior and differentiation
trajectory of NB cells.
Gli1 advances differentiation of SY5Y cells
To test further whether Gli1 advanced the differentiation of NB
cells in culture, we compared the transcriptional responses of SH-
SY5Y cells to either Gli1 transduction or treatment with the
differentiation agent RA. RNA from SY-GFP cells treated for 48
Figure 2. Enteric NC markers CGRP (A), and GFAP (B) were
expressed more strongly in GN than NB. Antibodies to CGRP
labeled rare cells (blue arrowheads) in NB and adrenal medulla (Ad),
while labeling neurons (blue arrowheads) and processes (blue arrows)
throughout both GNs and enteric ganglia (gut). Antibodies to GFAP
labeled stromal cords in NB and rare adrenal medullary cells (blue
arrowheads). In contrast, labeling was intense and widespread in GN
and in ganglia of the gut (outlines by dotted white lines).
doi:10.1371/journal.pone.0007491.g002
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was analyzed by microarray and the resulting datasets were
compared to determine the sets of genes differentially expressed in
response to RA. Comparison of three replicates of each condition,
with p,0.0001 defined a set of 326 genes differentially expressed
in SY-Gli compared to SY-GFP, and a set of 2123 differentially
expressed in SY-GFP treated with ATRA or vehicle. The overlap
of these two sets was striking: 147 genes were regulated by both
ATRA and Gli1 in the same direction (p,0.00001 by hypergeo-
metric test). The close correspondence between transcriptional
response to Gli1 and RA supports the interpretation that Gli1
drives NB cells toward differentiation.
The differential expression of HH pathway genes and targets in
GN, the divergence of GN from SNS fate, and the induction of
cranial and entericNCgenesinNBcellsbyGli1,suggestedthat HH
signaling might drive PNTs toward the GN phenotype. In order to
test the hypothesis that HH activity could induce PNTs to become
GNs, we determined whether the transcriptional response of NB
cells to Gli1 resembled the specific gene expression pattern of GN.
We compared the set of genes regulated by Gli1 in SY5Y cells to the
set of genes differentially expressed in GN, compared to NB. We
found highly significant overlap between the two sets. Of the 2108
genes found on the U95A array to be differentially expressed in GN
witha p-value,0.0001,1811 arerepresented onthe U1332.0array
and could be used for comparison. In our initial comparison of SY-
Figure 3. Gli1 slowed proliferation of NB cell lines while driving CGNPs to proliferate. A) Transduction of Gli1 decreased proliferation of
NB cell lines SY5Y, BE2(N), BE2(C) and BE2(S). Proliferation in SH-EP1 was relatively unaffected (P.0.05) while proliferation of CGCPs was increased 19-
fold. Error bars represent standard deviation normalized mean. B) Decreased proliferation of SY-Gli cells relative to SY-GFP was confirmed by
measuring the mitotic rate of both lines, expressed as PH3+ cells per 1000. Error bars represent standard deviation. C) Western blot of two
independent SY-Gli and SY-GFP cultures demonstrated the N-MYC expression was not affected by Gli1 transduction, while RET was strongly induced
by Gli1.
doi:10.1371/journal.pone.0007491.g003
Table 3. Measured abundance of mRNA for select genes
identified by microarray analysis as regulated by Gli1 in SY5Y
cells.
SY5Y GLI/GFP SY5Y GLI/GFP SH-EP1 GLI/GFP
p-value fold change fold change
microarray qRT-PCR qRT-PCR
MATN2 2.8E-12 28.9 625.4
KAL1 2.9E-11 176.3 10.9
PMP22 4.7E-09 2.0 2.0
IGFBP5 4.1E-08 3.1 1.6
NTRK2 1.3E-07 3.3 2.0
FDZ7 1.5E-07 2.0 1.3
EGFR 3.7E-07 3.0 1.4
WNT4a 4.5E-07 5.4 0.6
SOX2 3.2E-05 0.16 3.5
EDNRA 2.2E-08 2.7 1.1
RET 1.5E-07 4.4 1.5
VMAT2 8.2E-05 81.2 2.1
Genes up-regulated in GN are listed in bold.
doi:10.1371/journal.pone.0007491.t003
Table 4. Genetic determinants of diverse NC fates are
induced by Gli1 in SY5Y cells.
Cranial NC
genes
ENS
genes
Neural
NC fate
Bony
NC fate
Glial
NC fate
KAL1 RET RET NELL1 PMP22
EDNRA GFRA2 GFRA2 EDNRA
MSX2 VMAT2 MSX2
doi:10.1371/journal.pone.0007491.t004
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were differentially expressed with p,0.0001. Of these 193 genes, 57
genes were differentially expressed in GN compared to NB, a
correlation very unlikely to occur by chance (p,0.00001 by
hypergeometric test). Thus the effect of Gli1 transduction was to
slow the proliferation of SH-SY5Y cells, and induce a transcrip-
tional response that resembled both the response to RA and the
specific gene expression pattern of GN.
Absence of effect on N-Myc and up-regulation of RET by
Gli1
The decreased proliferation and advanced differentiation of NB
cells in response to Gli1 contrasted sharply with increased
proliferation of Gli1-transduced CGCPs. These alternative
responses to HH activity might be mediated by crucial, cell-
specific differences in the underlying transcriptional response to
Gli1. N-Myc is up-regulated by HH pathway activity in CGCPs
and functions as an essential effector of Shh driven proliferation
[37]. N-MYC is also an established oncogene in neuroblastoma.
We have previously found that the RET proto-oncogene is up-
regulated by RA in NB cell lines and plays an essential role in RA-
induced differentiation [38]. We investigated the potential
induction of N-MYC by Gli1 in PNTs by comparing N-MYC
mRNA and protein levels in SY-Gli and SY-GFP cells. N-MYC
mRNA expression measured by microarray did not correlate with
Gli1 transduction (data not shown). Western blot (Fig. 3c)
confirmed that N-MYC protein levels were not substantially
altered by Gli1. In contrast, RET protein was strongly induced in
SY-Gli cells, consistent with the promotion of differentiation.
Discussion
Differentiation in GN: SNS vs ENS phenotype
Transcriptome analysis of PNTs revealed divergent differentiation
trajectories of GN and NB. Among the many differentially expressed
genes, we were able to discern a clear shift in markers for NC subsets:
NBsexpressedsympatheticmarkerswhile GNsexpressed apatternof
differentiation markers most consistent with the ENS. Like
developing ENS cells, GNs demonstrated activity of the HH
pathway, marked by expression of both GLI1 and GLI3 and
modulation of known HH target expression in predictable directions.
The ENS phenotype of neurons and glia in GN represents
divergence from the characteristic pattern of SNS development in
PNTs. GNs typically occur at sites along the sympathetic chain,
and their progenitor cells have thus migrated as sympathoblasts.
At some point after migration, however, under the influence of
HH, these progenitors differentiate as ENS neurons and glia. The
phenomenon of GNs arising from sites of metastatic NB,
moreover, indicates this divergence may occur after malignant
transformation has taken place. While the characterization of GNs
as resembling ENS is novel, it has long been known that children
with GN may present with gastrointestinal complaints. Enteric
dysmotility in these patients has been attributed to secretion by the
tumor of enteric neuropeptides [39]. The present findings place
this enteric presentation within the context of NC development.
HH pathway as morphogenic and tumor suppressive
During development, HH is both a mitogen and a morphogen,
regulating both proliferation and differentiation. The diverse
potential effects of HH signaling allow for a range of plausible roles
in GN pathogenesis. Although HH-mediated Gli1 activation can
drive proliferation and tumorigenesis of cerebellar neural progen-
itors, and we found that Gli1 transduction increased the
proliferation of CGCPs, in NB cells, Gli1 inhibited proliferation
and induced expression of RA-responsive genes and genes up-
regulated in GN. Our observation that Gli1 decreased proliferation
of NB cells is not consistent with an oncogenic effect.
We suggest that HH acts in GN as a morphogen, driving not
proliferation, but specific fate choice, promoting PNT differenti-
ation rather than growth. In the developing zebrafish retina, SHH
signaling promotes the differentiation of neuroblasts, and inhibi-
tion of SHH supports progenitor proliferation [40]. In hippocam-
pal neural stem cells, moreover, GLI1 can limit proliferation by
inducing apoptosis [41]. Accordingly, GNs may demonstrate the
highest differentiation specifically because they have achieved the
highest levels of HH activity, depleting tumor stem cells through
apoptosis or differentiation. While we did not observe prominent
induction of apoptosis by SY-Gli cells, we cannot rule out an
apoptotic effect on a sub-population of cells with stem-like
properties. A tumor suppressive role for HH signaling would
account for the benign, differentiated phenotype of GNs and for
the decrease in proliferation of NB cells on transduction with Gli1.
This hypothesis may be tested in vivo, and the role of HH signaling
in NC development and PNT pathogenesis may be further
elucidated, through xenograft studies and animal primary PNTs
models, using targeted activation of Smo to drive HH activity [42]
and targeted activation of MYCN to induce PNTs [43].
DHH and Schwann cell mediated differentiation in GN
The mechanism of HH pathway activation in GN is not clear. The
HH pathway may be activated through a cell autonomous mechanism,
as seen in medulloblastomas in which mutant SMO is constitutively
active [9]. We did not detect differential expression of SMO in GN, but
the possibility of activating mutations in GN remains to be evaluated.
Alternatively, the HH signaling may be activated by ligand binding.
HH signaling in GN could be mediated by DHH, which, like
GLI1 and GLI3 is differentially expressed in these benign tumors.
Schwann cells in peripheral nerves secrete DHH [44], and GNs
are largely composed of cells that resemble Schwann cells. Several
lines of evidence have demonstrated that Schwann cells secrete
factors that promote differentiation of NB cells [45,46]. DHH may
contribute to this inductive interaction, and glial cells within GN
may, unlike typical Scwhann cells [47], respond to DHH in an
autocrine manner, to enforce and advance differentiation.
Materials and Methods
Human Tissue Samples
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Memorial Sloan-Kettering Cancer Center Institutional Review
Board (IRB) and Human Tumor Utilization Committee (HTUC).
All patients provided written informed consent for the collection of
samples and subsequent analysis.
Cell culture techniques
Neuroblastoma cell lines were kindly provided by R. Ross and B.
Spengler (Fordham University, Fordham, NY). HEK293E cells
(Invitrogen) were used for retroviral packaging. All cell lines were
maintained in Opti-MEM with Glutamax (cat#51985; Invitrogen)
supplemented with 10% FCS and penicillin/streptomycin at 37uCi na
humidified environment with 5% CO2. For RA treatment, SY-GFP
cells were plated in triplicate sets in 10 cm plates and allowed to adhere
for 24 hours, after which 1/1000
th volume of 10 mM retinoic acid
dissolved in 100% EtOH, or vehicle alone was added to the medium.
After 48 hours in ATRA, cells were processed for microarray.
Murine Gli1 and GFP were transduced into NB cells using a bi-
cistronic retroviral plasmid, pLZIR-GLI (gift of Robert Wechsler-
Hedgehog & Neuroblastic Tumors
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GFP, using pWZL-GFP. Retroviral stocks were prepared by co-
transfecting HEK293E cells with Gag-Pol and VSVG plasmids along
with the either pLZIR-GLI or pWZL-GFP, using Fugene 6.0
(cat#11814443001; Roche). Packaging cells were transferred to 32 C
24 hours after transfection, and viral stocks were harvested at 48 and
36 hours. For transduction, NB cells were exposed to retroviral stock
at 32 C for 4–6 hours, recovered for 3–4 days at 37 C and sorted for
GFP expression by FACS. GFP+ populations were then recovered
and expanded through 2–3 passages before use in experiments.
Proliferating cells were labeled by EdU and Alexa647 using the
Invitrogen Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay
kit (cat# A10202), then analyzed by FACS. For PH3 and caspase
staining, 50,000 cells per well were plated in 96 well plates and
maintained in culture for 2 days, then fixed in 4% formaldehyde,
immunostained for PH3 and counterstained with DAPI. We
performed automated quantification of PH3+ and DAPI+ cells
with 8-fold replicates using an INCell 1000 automated microscope
(GE/Amersham Biosciences).
Microarray analysis
Microarray hybridization of tumor derived samples was carried out
on Affymetrix U95A chips, as previously described [48]. RNA was
prepared from SY-Gli and SY-GFP cell lines using Trizol Reagent
(Invitrogen cat# 15596026), processed and analyzed on Affymetrix
U133 2.0 chips, according to manufacturer’s protocol. All microarray
expression data were processed with Robust Multichip Analysis (RMA;
R software; the R Foundation for Statistical Computing) [49].
Differential expression analysis was performed to identify genes
between sample groups applying an Empirical Bayes t test to each
gene [14]. All microarray data are described in accordance with
MIAME guidelines. Microarray data are deposited in the caArray
Array Data Management System, Experiment Identifier gersh-00292.
To derive gene lists for comparison, a p-value cutoff of 0.0001
wasused to selectdifferentiallyexpressedgenes.Thenumberoftests
(i.e. probesets) with p,0.0001 expected by chance equals 0.00016
total number of probesets. For the U95 platform, which is used for
the tumor sample study, the total of number of probesets is 12,533
and hence 1 probeset is expected to have a p-value,0.0001 just by
chance. For the U133A platform, which is used for the cell line
study, the total of number of probesets is 22,215 and hence 2
probesets are expected to have a p-value,0.0001 just by chance.
The actual sets of genes demonstrating differential expression with
p,0.0001 were compiled, and a hypergeometric test was then used
to calculate the probability of overlapping sets.
Quantitative real-time reverse transcriptase PCR (qRT-PCR)
We confirmed gene expression patterns noted by microarray by
qRT-PCR using a 2-step method. Total RNA for template was
purified from tumor and cell line samples independent from those used
for microarray; 12–18 tumor samples and 12 cell line samples were
used in each qRT-PCR assay. First strand cDNA was synthesized
using the Superscript III kit (Invitrogen). We performed qRT-PCR
reactions on the BioRad iCycler and IQ SYBR Green Master Mix
(170–8882; BioRad). All reactions were performed in duplicate. All
primer pairs were designed to span at least 1 intron-exon boundaries,
except for VIP, which has no introns (Table S3). Each primer pair was
validated by RT-PCR and the products were cloned and sequenced to
confirm specificity. Cloned PCR products were then used as copy
number standards for qRT-PCR. Each primer pair yielded measured
Ct values in control reactions that varied linearly with the log of copy
number over at least 6 orders of magnitude. We normalized all values
to the measured expression of beta actin (BA). Fold change was
computed by comparing the median copy number for each group.
Immunocytochemistry and Western blots
All immunocytochemistry was performed on paraffin embedded
material from pathology archives of The Memorial Sloan-Kettering
Cancer Center (MSKCC). Antigen retrieval and staining techniques
were as previously described [4]. Cultured cells were not subjected to
antigen retrieval. For Western blots, SY-Gli and SY-GFP cells were
prepared in triplicate wells, and lysed in situ, then subjected to SDS-
PAGE, and developed using chemiluminescence. Sources of primary
antibodies and concentrations used are as listed ( Table S3).
Supporting Information
Table S1 Genes differentially expressed in GN compared to NB.
Mean values are computed from log2 transformed expression
values. The difference in log2 transformed means is therefore
equal to log2 (fold change).
Found at: doi:10.1371/journal.pone.0007491.s001 (4.10 MB
DOC)
Table S2 Genes differentially expressed in SY5Y cells tranduced
with Gli1 and GFP or GFP only. Mean values are computed from
log2 transformed expression values. The difference in log2
transformed means is therefore equal to log2 (fold change).
Found at: doi:10.1371/journal.pone.0007491.s002 (0.33 MB
DOC)
Table S3 Primers and antibodies used
Found at: doi:10.1371/journal.pone.0007491.s003 (0.03 MB
DOC)
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